Not checked for notices yet.
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
Jiong Wu, Zefei Jiang, Zhenzhen Liu and 19 more
BMC Medicine · 2022
doi:10.1186/s12916-022-02708-3
Cited by papers we hold 2
- HER2-targeted therapies in cancer: a systematic review · 2024No notice
- Therapeutic advances of targeting receptor tyrosine kinases in cancer · 2024No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.